FREEdom Coin (FREE) news

Jim Cramer on nVent Electric: "It's Like a Mini Vertiv"

VNET Group (VNET) Soars 14.7% as Earnings Loom, Double-Digit Growth Eyed

Scotiabank Lifts AT&T (T) Price Target after Positive Industry Signals

Is Innodata's Hybrid AI Strategy Set to Boost Margins Ahead?

C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data

Trimble Inc. (TRMB) Releases Financial Results for Q4 2025 and FY 2025

Benchmark Downgrades Permian Resources Corporation (PR) to 'Hold'

Cooper-Standard Holdings (CPS) Reports $2.74B Sales and $209.7M Adjusted EBITDA for 2025

Johnson and Johnson (JNJ) Reports Positive Phase 1b Cancer Data

Citius Pharma (CTXR) Becomes Revenue-Generating With the Commercial Launch of LYMPHIR

Take-Two (TTWO) Reports FQ3 2026 Net Bookings of $1.76B, Beats Guidance

Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B

Piper Sandler Neutral on NICE Ltd. (NICE) Post Q4

Roth Capital Lowers PT on Playtika Holding (PLTK), Keeps a Hold Rating

SM Energy Company (SM) Among Seven Undervalued Stocks Amid Rising Oil Risks

RBC Capital Lowers Its Price Target on Viridian Therapeutics, Inc. (VRDN) to $42 and Maintains an Outperform Rating

Jim Cramer on Public Service Enterprise Group: "I Don't Want You to Buy Any"

William Blair Upgrades Aehr Test Systems, Inc. (AEHR) to Outperform from Market Perform - Here's Why

Why Victoria's Secret (VSCO) Stock Is Down Today

Jim Cramer on First Solar: "We Gotta Wait Another Quarter for That One"

Jim Cramer on First Solar: "We Gotta Wait Another Quarter for That One"

Jim Cramer on Americas Gold and Silver Corporation: "I Always Demand That People Do Some Selling After Parabolic Moves"

KeyBanc Remains a Buy on Samsara (IOT)

AtaiBeckley (ATAI) to Initiate Phase 3 Depression Study Following Positive FDA Meeting

VinFast Auto Ltd (VFS) Expands Partnerships and Reports Delivery Growth

What To Expect From Burlington's (BURL) Q4 Earnings

Canaccord Initiates Aurora Cannabis Inc. (ACB) With C$10 Price Target

Piper Sandler Raises Slide Insurance Holdings, Inc. (SLDE) Price Target to $24 from $22

1 Growth Stock with All-Star Potential and 2 We Question

Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval